PMV Pharmaceuticals, an early stage biotech developing targeted therapies for cancer, raised $212 million by offering 11.8 million shares at $18, the high end of the range of $16 to $18.
The Cranbury, NJ-based company plans to list on the Nasdaq under the symbol PMVP. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as lead managers on the deal.
